CUPERTINO, Calif., Oct 4, 2002 /PRNewswire-FirstCall via COMTEX/ — DURECT
Corporation (Nasdaq: DRRX) announced today that it will present at the UBS
Warburg Global Life Sciences Conference. The conference is being held at The
Plaza Hotel in New York City. Thomas A. Schreck, Chief Financial Officer, will
be presenting at the conference on Monday, October 7, 2002 at 3:00 p.m. EDT.
A live audio webcast of Mr. Schreck’s presentation will be available by
accessing UBS Warburg’s homepage at http://www.ubswarburg.com and clicking on
UBS Warburg Conferences in the lower right hand corner. Follow the link for the
webcast under the Global Life Sciences Conference heading.
DURECT Corporation (www.www.durect.com) is pioneering the development and
commercialization of pharmaceutical systems for the treatment of chronic
debilitating diseases and enabling biotechnology-based pharmaceutical products.
DURECT’s goal is to deliver the right drug to the right site in the right amount
at the right time. In November 2001, DURECT completed a pilot phase III program
for the CHRONOGESIC(TM) (sufentanil) Pain Therapy System, a 3-month product for
the treatment of chronic pain. DURECT owns three proprietary drug delivery
platform technologies, including the SABER(TM) Delivery System (a patented and
versatile depot injectable useful for protein delivery), the MICRODUR(TM)
Biodegradable Microparticulates (microspheres injectable system) and the
DURIN(TM) Biodegradable Implant (drug-loaded implant system).
NOTE: CHRONOGESIC(TM) is a trademark of DURECT Corporation. SABER(TM),
MICRODUR(TM) and DURIN(TM) are trademarks of Southern BioSystems, Inc., a wholly
owned subsidiary of DURECT Corporation. Other trademarks referred to belong to
their respective owners.
The statements in this press release regarding DURECT’s products in development
and product development plans, are forward-looking statements involving risks
and uncertainties that can cause actual results to differ materially from those
in such forward-looking statements. Potential risks and uncertainties include,
but are not limited to, DURECT’s ability to research, develop, manufacture and
commercialize its products, obtain product and manufacturing approvals from
regulatory agencies, manage its growth and expenses, finance its activities and
operations, as well as marketplace acceptance of DURECT’s products. Further
information regarding these and other risks is included in DURECT’s Annual
Report on Form 10-K for the fiscal year ended December 31, 2001 filed with the
SEC on March 28, 2002, under the heading “Factors that may affect future
results,” and other periodic reports filed with the SEC. CHRONOGESIC is under
development by DURECT and has not been submitted or approved for
commercialization by the US Food and Drug Administration or other health
SOURCE DURECT Corporation
Schond L. Greenway, Senior Director, Investor Relations and
Strategic Planning of DURECT Corporation, +1-408-777-1417, or
/Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, +1-888-776-6555 or +1-212-782-2840
Copyright (C) 2002 PR Newswire. All rights reserved.